$14.15
+4.73 (+50.21%)
Open$13.70
Previous Close$9.42
Day High$18.21
Day Low$12.61
52W High$36.99
52W Low$2.82
Volume—
Avg Volume32.75M
Market Cap38.55M
P/E Ratio—
EPS$-0.33
SectorBiotechnology
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.95M | 2.89M | 2.41M |
| Net Income | -877,894 | -779,690 | -617,534 |
| Profit Margin | -29.8% | -27.0% | -25.7% |
| EBITDA | -957,867 | -819,475 | -798,278 |
| Free Cash Flow | -748,445 | -747,364 | -598,338 |
| Rev Growth | +6.0% | +2.0% | +0.0% |
| Debt/Equity | 0.66 | 0.66 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |